Selarl Retine Tourny

At Selarl Retine Tourny in Bordeaux, the clinical trial portfolio focuses on ophthalmology and a range of eye diseases, especially conditions that affect the retina and central vision. The research is centered on improving vision outcomes, testing longer-lasting treatment options, and better understanding how to manage chronic retinal disorders.

• Diabetic macular oedema and treatment strategies aimed at preserving visual acuity
• Macular edema secondary to retinal vein occlusion with a focus on improving swelling-related vision loss
• Neovascular age-related macular degeneration research examining new ways to control disease activity and reduce treatment burden

The studies at this site also include work on anti-VEGF therapies, intravitreal implants, and longer-acting delivery systems, reflecting a broader effort to make retinal treatment more effective and more convenient for patients.

Several trials at this hospital/clinic are evaluating new approaches for neovascular age-related macular degeneration, a major cause of vision loss in older adults. The main goal is to test whether newer therapies can maintain or improve vision while reducing how often patients need eye injections.

• Faricimab studies assessing visual acuity outcomes in age-related macular degeneration
• Ranibizumab delivered through the Port Delivery System to support longer treatment intervals
• Aflibercept research comparing extended treatment schedules with standard care

These trials are designed to evaluate efficacy, safety, and the potential for more durable control of retinal disease.

Research in diabetic macular oedema at Selarl Retine Tourny is focused on reducing retinal swelling and improving day-to-day vision for people affected by diabetes-related eye disease. The studies are exploring whether newer treatment plans can provide better visual outcomes and sustained symptom control.

• Dexamethasone implant regimens for vision improvement in diabetic macular oedema
• Aflibercept comparisons in macular edema linked to retinal vein occlusion
• Assessment of treatment effectiveness in chronic retinal swelling conditions

This area of research aims to refine intraocular treatment options and support more reliable management of persistent macular fluid.

The site also contributes to studies involving large choroid melanoma treated with proton therapy, showing interest in the overlap between ophthalmology and ocular oncology. These trials look beyond tumor control to address eye-related complications that can follow treatment.

• Prevention of neovascular glaucoma after proton therapy
• Use of preventive anti-VEGF injections to reduce post-treatment complications
• Long-term monitoring of safety and eye health after cancer-directed therapy

Overall, this research supports better management of rare but serious eye conditions while aiming to protect vision during and after cancer treatment.

A key theme across the research program is the search for treatments that remain effective over time while lowering the burden of frequent clinic visits. The trials are examining how durable therapies may improve both convenience and ongoing disease control in people with chronic retinal disorders.

• Long-term safety and tolerability of sustained retinal therapies
• Reduction of injection burden in neovascular age-related macular degeneration
• Evaluation of lasting visual preservation with newer gene-based and injectable approaches

These studies reflect a practical research focus on balancing effectiveness, safety, and patient-friendly treatment schedules.